The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry

Special Section

Early Career Psychiatrists

The objective of the Early Career Psychiatrists section is to encourage the academic development of early career psychiatrists. Manuscripts selected for this section will be those deemed through the review process to represent excellent work from the next generation of researchers in psychiatry.

Eligibility criteria for first authors:

  • Trained psychiatrists with an MD, MD/PhD, or DO degree
  • Less than 5 years from completion of training
  • Current academic rank no higher than Assistant Professor

Page 2

JCP
Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report
Original Research

November 15, 2023

Quality of life is an important patient-centric outcome. Using machine learning methods, this study found that quality of life improvement with antidepressant treatment can be predicted using early depression…
, , , et al
JCP
Medication Adherence in a Transdiagnostic FEP Sample
Original Research

November 1, 2023

Thirty percent of patients with first-episode psychosis showed non-adherence to medication over a period of up to 5½ years. Treatment factors such as the type or dose of antipsychotic…
, ,
JCP
Coprescribing of Z-Drugs and Opioids During COVID-19
Original Research

September 11, 2023

Coprescribing of nonbenzodiazepine sedative-hypnotics, or “Z-drugs,” with opioids was more common among older patients, although the odds of coprescription among patients overall decreased over the COVID-19 lockdown period.
, , , et al
JCP
Alcohol Use Disorder Treatment in Sexually and Gender Diverse Patients
Original Research

August 28, 2023

Sexually and gender diverse (SGD) patients had significantly higher rates of both AUD diagnosis and care utilization compared with non-SGD patients.
, , , et al
JCP
Race, Ethnicity, and ED Disposition for Mental Health Visits
Original Research

July 26, 2023

Black patients, especially Black male patients, are overrepresented in inpatient psychiatry. This study examined biases in admission rates among Black patients and, specifically, Black male patients with or without…
,
JCP
Subcallosal Cingulate Gyrus Deep Brain Stimulation for TRD
Original Research

June 28, 2023

DBS targeting the subcallosal cingulate gyrus to treat depressive symptoms resulted in response and remission rates of 75% and 62.5%.
, , , et al
JCP
Mild Vitamin C Deficiency Is Common in Psychiatric Inpatients
Original Research

June 14, 2023

Almost two-thirds of inpatients met criteria for mild vitamin C deficiency, and folate and vitamin D levels strongly predicted vitamin C levels.
, ,
JCP
Weight Loss and Lifestyle Intervention for Obstructive Sleep Apnea
Original Research

June 12, 2023

A weight loss and lifestyle intervention improved OSA-related impaired daily functioning and psychiatric symptoms.
, , , et al
JCP
Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review
Systematic Review

May 10, 2023

Randomized trials of psychedelics underutilize blind assessment, active drug controls, and testing psychological support against minimal-support conditions—elements that would improve quality or provide important information.
, , , et al
JCP
Ketamine vs Esketamine for TRD
Original Research

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
, , , et al
JCP
Comparison of Catatonia Risk of 30 Antipsychotics
Original Research

December 14, 2022

In this postmarketing study, first-generation antipsychotics were associated with a greater risk of catatonia syndromes compared to second-generation antipsychotics.
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe